XOMA Corporation (XOMA, Financial) experienced a significant stock movement, with its price rising by 5.45% to $32.70 per share. The trading volume reached 32,220 shares, translating to a turnover rate of 0.27% and a price fluctuation of 6.80%.
According to the latest financial reports, XOMA recorded a revenue of $7.20 million, but faced a net loss of $17.24 million, resulting in an earnings per share (EPS) of -$1.59. The company's gross profit stood at $7.19 million, with a negative price-to-earnings (P/E) ratio of -10.59. Currently, there are no institutional ratings recommending a buy, hold, or sell for XOMA stock.
Within the biotechnology sector, where XOMA operates, the overall growth was 0.22%. Notable gainers in this sector included Poseida Therapeutics, Inc., Surrozen Inc C/Wts 01/08/2031 (To Pur Com), and Ocean Biomedical Inc C/Wts 14/02/2028 (To Pur Com). Active stocks in the sector were Elevai Labs, Inc., Cassava Sciences, and Tc Biopharm (Holdings) Plc, with turnover rates of 50.97%, 49.38%, and 32.52% respectively. Stocks with significant price fluctuations included Rocket Pharmaceuticals Inc C/Wts 02/09/2026 (To Pur Com), Tc Biopharm (Holdings) Plc C/Wts 10/02/2028 (To Pur Ads), and Lakeshore Biopharma Co., Ltd, with amplitudes of 85.82%, 57.50%, and 55.39% respectively.
XOMA Royalty Corp is a biotechnology royalty aggregator, playing a crucial role in helping biotech companies achieve their goals of improving human health. It secures potential future economic benefits from pre-commercial candidates licensed to pharmaceutical or biotech companies. When XOMA receives future economic rights, the sellers receive non-dilutive, non-recourse funding to advance their internal drug candidates or for general corporate purposes.
